IGF-1 LR3 (Long R3 IGF-I)

Experimental Peptide

Long R3 IGF-I is an engineered IGF-I analogue with an Arg substitution at position 3 and a 13-amino-acid N-terminal extension. It is distinct from endogenous IGF-1 and prescription recombinant human IGF-I; vendor dosing is not clinical evidence.

Pharmacokinetic model

A route-level PK model for igf-1 lr3 (long r3 igf-i) is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Experimental Peptide
Suggested cadence: once daily

Research behind this entry

Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency Grahnen A, Kastrup K, Heinrich U, Gourmelen M, Preece MA, Vaccarello MA, Guevara-Aguirre J, Rosenfeld RG, Sietnieks A · Acta Paediatrica Supplement, 1993 DOI
This human pharmacokinetic study administered recombinant human IGF-I, not Long R3 IGF-I. It supplies parent-hormone context only; LR3's sequence extension and altered IGF-binding-protein affinity prevent transfer of…

1 published study referenced in the app, each with a plain-language summary.